WALTHAM, Mass., March 11, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) (the "Company") today announced that it has received correspondence from The NASDAQ Stock Market LLC ("NASDAQ") confirming that the Company has evidenced compliance with the requirements for continued listing on The NASDAQ Capital Market. Accordingly, the NASDAQ compliance matter has been closed.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 (R) Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com . The BG Medicine, Inc. logo is available for download here.
CONTACT: Corporate Communications +1 (781) 890-1199 BG Medicine, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts